Literature DB >> 2437014

Functional and molecular aspects of human T lymphocyte activation via T3-Ti and T11 pathways.

A Alcover, D Ramarli, N E Richardson, H C Chang, E L Reinherz.   

Abstract

Two pathways of human lymphocyte activation are known to exist on T-lineage cells. The first involves the T-lymphocyte receptor for antigen (T3-Ti) which operates in conjunction with gene products of the MHC complex and is a molecular complex composed of 5 polypeptide chains. Both the 49KD alpha and 43KD beta chains are immunoglobulin-like and thus contain variable domains responsible for ligand binding. In contrast, the 20-25KD T3 gamma, delta and epsilon chains are monomorphic structures presumably involved in transmembrane signalling. The alpha and beta subunits are disulfide bonded to each other and held in noncovalent association with the T3 chains. The second pathway involves the 50KD T11 sheep erythrocyte binding protein. The T11 pathway is operational during early intrathymic ontogeny, prior to T3-Ti receptor expression. Under physiologic conditions, T3-Ti and T11 pathways appear to function in series with T11, representing a more "nuclear proximal" structure. However, each pathway, independently of the other, can activate the phosphoinositol cascade and lead to elevation in cytosolic free calcium. The latter is critical for transcriptional activation of the endogenous IL-2 gene. The ability of the T3-Ti complex to regulate T11-mediated activation is discussed with reference to its possible role in thymic selection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2437014     DOI: 10.1111/j.1600-065x.1987.tb00498.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  31 in total

Review 1.  The role of adhesion molecules in endothelial cell accessory function.

Authors:  J R Westphal; R M de Waal
Journal:  Mol Biol Rep       Date:  1992-11       Impact factor: 2.316

2.  Intrinsic B lymphocyte defect in untreated patients with Hodgkin's disease.

Authors:  F Griesinger; L Bergmann; R Barot-Ciorbaru; P S Mitrou
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Calcium influx and intracellular calcium release in anti-CD3 antibody-stimulated and thapsigargin-treated human T lymphoblasts.

Authors:  B Sarkadi; A Tordai; L Homolya; O Scharff; G Gárdos
Journal:  J Membr Biol       Date:  1991-07       Impact factor: 1.843

Review 4.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

5.  Amplification of T cell blastogenic responses in healthy individuals and patients with acquired immunodeficiency syndrome.

Authors:  P E Harris; K Strba-Cechova; P Rubinstein; D Mann; D W King; N Suciu-Foca
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

6.  Molecular basis for the aberrant expression of T cell antigens in postthymic T cell malignancies.

Authors:  I J Su; S P Balk; M E Kadin
Journal:  Am J Pathol       Date:  1988-08       Impact factor: 4.307

7.  Monoclonal antibodies specific for murine CD2 reveal its presence on B as well as T cells.

Authors:  H Yagita; T Nakamura; H Karasuyama; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

8.  Recombinant interleukin 2 therapy in severe combined immunodeficiency disease.

Authors:  R Pahwa; T Chatila; S Pahwa; C Paradise; N K Day; R Geha; S A Schwartz; H Slade; N Oyaizu; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

9.  T-lymphocytes in experimental Leishmania amazonensis infection: comparison between immunized and naive BALB/c mice.

Authors:  M Pompeu; A L Freitas; G A dosReis; M Barral-Netto
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

10.  Characterization of Ca2+ and K+ currents in the human Jurkat T cell line: effects of phytohaemagglutinin.

Authors:  G Dupuis; J Héroux; M D Payet
Journal:  J Physiol       Date:  1989-05       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.